ARDX Ardelyx Inc.

5.60
+0.05  (1%)
Previous Close 5.55
Open 5.60
Price To book 1.83
Market Cap 265692778
Shares 47,445,139
Volume 133,214
Short Ratio 4.11
Av. Daily Volume 276,259

SEC filingsSee all SEC filings

  1. 8-K - Current report 171090432
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 171063076
  3. 8-K - Current report 171052679
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016499
  5. 8-K - Current report 171016378

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due early 4Q 2017. Estimate November 15, 2017 as latest possible date using company guidance of "early 4Q".
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data due 4Q 2017.
RDX7675
Hyperkalemia
Phase 3 trial initiation announced January 3, 2017.
RDX227675
Hyperkalemia
Phase 3 released February 15, 2017 - primary endpoint met. Second Phase 3 trial to be initiated October 2017.
Tenapanor
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. Edited Transcript of ARDX earnings conference call or presentation 9-Aug-17 12:00pm GMT
  2. Ardelyx reports 2Q loss
  3. Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results
  4. Investor Network: Ardelyx, Inc. to Host Earnings Call
  5. Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
  6. LD Micro Index Reconstitution as of August 1, 2017
  7. Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant
  8. 5 Breakout Stocks Offering Phenomenal Returns
  9. With Ardelyx's Fall, Does Synergy Now Have a Clear Path to Victory?
  10. What Do the Ardelyx Numbers Mean for the Company?
  11. Blog Coverage: Ardelyx Reports Successful Trial Results for Treatment of Patients with Irritable Bowel Syndrome with Constipation
  12. Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
  13. Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress
  14. Ardelyx To Present at Upcoming Spring Medical Meetings
  15. Adaptimmune Broadens Executive Team
  16. Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
  17. Wedbush Has A New Best Idea For 2017: Ardelyx
  18. Ardelyx, Inc. :ARDX-US: Earnings Analysis: Q4, 2016 By the Numbers

SEC Filings

  1. 8-K - Current report 171090432
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 171063076
  3. 8-K - Current report 171052679
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016499
  5. 8-K - Current report 171016378
  6. 8-K - Current report 17923841
  7. 8-K - Current report 17903552
  8. 8-K - Current report 17836371
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17816315
  10. EFFECT - Notice of Effectiveness 17816003